CASI Pharmaceuticals (CASI)

Company Profile

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.

Company profile

Ticker

CASI

Exchange

NASDAQ

Website

www.casipharmaceuticals.com

CEO

Wei-Wu He

Incorporated

Delaware

Location

Maryland

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...

Former names

CASI Pharmaceuticals, Inc., ENTREMED INC

SEC CIK

0000895051

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

CASI Pharmaceuticals (China) Co., Ltd, a company of limited • Beijing Zhongbai Biotechnology Co., Ltd. • Miikana Therapeutics, Inc. • CASI Biopharmaceuticals (WUXI) Co., Ltd., a company of limited • CASI Pharmaceuticals (WUXI) Co., Ltd., a company of limited • CASI Pharmaceuticals (Hainan) Co., Ltd., a company of limited ...

IRS number

581959440

CASI stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

EFFECT

Notice of effectiveness

27 Mar 23

15-12G

Securities registration termination

22 Mar 23

S-8 POS

Registration of securities for employees (post-effective amendment)

21 Mar 23

S-8 POS

Registration of securities for employees (post-effective amendment)

21 Mar 23

S-8 POS

Registration of securities for employees (post-effective amendment)

21 Mar 23

S-8 POS

Registration of securities for employees (post-effective amendment)

21 Mar 23

POS AM

Prospectus update (post-effective amendment)

21 Mar 23

8-K

Submission of Matters to a Vote of Security Holders

14 Feb 23

Entry into a Material Definitive Agreement

31 Jan 23

Transcripts

View all

CASI

Earnings call transcript

2022 Q2

12 Aug 22

CASI

Earnings call transcript

2022 Q1

12 May 22

CASI

Earnings call transcript

2021 Q4

28 Mar 22

CASI

Earnings call transcript

2021 Q3

13 Nov 21

CASI

Earnings call transcript

2021 Q2

13 Aug 21

CASI

Earnings call transcript

2021 Q1

19 May 21

CASI

Earnings call transcript

2020 Q3

10 Nov 20

CASI

Earnings call transcript

2020 Q2

10 Aug 20

Latest ownership filings

View all

FEDERATED HERMES, INC.

9 Feb 23

SC 13G/A

FEDERATED HERMES, INC.

Financial summary

Financial statements Chart CASI financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	29.24 mm	29.24 mm	29.24 mm	29.24 mm	29.24 mm	29.24 mm
Cash burn (monthly)	(no burn)	1.99 mm	2.12 mm	2.82 mm	2.17 mm	2.32 mm
Cash used (since last report)	n/a	12.01 mm	12.78 mm	17.03 mm	13.12 mm	14.02 mm
Cash remaining	n/a	17.24 mm	16.47 mm	12.22 mm	16.12 mm	15.22 mm
Runway (months of cash)	n/a	8.7	7.8	4.3	7.4	6.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

CASI institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	209	201	+4.0%
Opened positions	26	20	+30.0%
Closed positions	18	38	-52.6%
Increased positions	70	80	-12.5%
Reduced positions	81	79	+2.5%

13F shares	Current	Prev Q	Change
Total value	802.89 bn	957.73 mm	+83733.2%
Total shares	35.94 mm	35.12 mm	+2.4%
Total puts	9.10 k	31.10 k	-70.7%
Total calls	46.10 k	68.70 k	-32.9%
Total put/call ratio	0.2	0.5	-56.4%

Largest owners	Shares	Value	Change
BLK Blackrock	7.04 mm	$197.23 bn	-1.5%
Jack Y. Zhang	6.83 mm	$0.00	0.0%
FHI Federated Hermes	3.28 mm	$92.02 bn	+0.6%
Vanguard	2.62 mm	$73.46 bn	+0.6%
Dimensional Fund Advisors	1.87 mm	$52.42 bn	+1.5%
STT State Street	1.36 mm	$38.07 bn	NEW
T. Rowe Price	789.17 k	$22.16 bn	-2.4%
Geode Capital Management	722.28 k	$20.28 bn	+2.0%
IVZ Invesco	645.96 k	$18.10 bn	+9.9%
MS Morgan Stanley	603.05 k	$16.90 bn	-15.1%

Largest transactions	Shares	Bought/sold	Change
STT State Street	1.36 mm	+1.36 mm	NEW
Pacer Advisors	231.01 k	+231.01 k	NEW
Fuller & Thaler Asset Management	500.07 k	-215.12 k	-30.1%
Citadel Advisors	42.51 k	-132.76 k	-75.7%
Lam	130.25 k	+130.25 k	NEW
Allspring Global Investments	110.37 k	-116.16 k	-51.3%
BLK Blackrock	7.04 mm	-109.04 k	-1.5%
MS Morgan Stanley	603.05 k	-107.34 k	-15.1%
JPM JPMorgan Chase & Co.	113.75 k	-105.93 k	-48.2%
GS Goldman Sachs	267.27 k	+92.92 k	+53.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CASI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
8 Sep 22	Huang James	Common Stock	Buy	Acquire P	Yes	No	4.2831	33,300	142.63 k	371,517
7 Sep 22	Alexander A Zukiwski	Employee Stock Option Common Stock	Grant	Acquire A	No	No	15.2	3,000	45.60 k	3,000
7 Sep 22	Huang James	Common Stock	Buy	Acquire P	Yes	No	3.9965	3,111	12.43 k	338,217
6 Sep 22	Huang James	Common Stock	Buy	Acquire P	Yes	No	3.8932	19,162	74.60 k	335,106
2 Sep 22	Huang James	Common Stock	Buy	Acquire P	Yes	No	3.7413	400	1.50 k	315,944
1 Sep 22	Huang James	Common Stock	Buy	Acquire P	Yes	No	3.7229	11,821	44.01 k	315,544
31 Aug 22	Huang James	Common Stock	Buy	Acquire P	Yes	No	3.745	24,975	93.53 k	303,723
26 Aug 22	Huang James	Common Stock	Buy	Acquire P	Yes	No	3.7488	39,527	148.18 k	278,748
24 Aug 22	Huang James	Common Stock	Buy	Acquire P	Yes	No	3.7502	5,000	18.75 k	239,221
23 Aug 22	Huang James	Common Stock	Buy	Acquire P	Yes	No	3.4998	40,000	139.99 k	234,221

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

21 Mar 23

BEIJING, March 21, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

6 Jan 23

~ NMPA approved CB-5339 CTA for Multiple Myeloma indication ~ ~ Expected enrollment to begin in 2023 ~ ROCKVILLE, Md. and BEIJING, Jan. 6, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S.